Contact Us |
* The committee would also like to acknowledge the important contributions to the research focus and operations of the committee by Paul O’Donnell, MD, who ended his tenure on the committee in 2016.
The research priority of the Donor Health and Safety Working Committee (DHSWC), now in its twelfth year, is to understand the impact of donation on both related and unrelated hematopoietic stem cell donors. Several important retrospective and prospective studies over the past five years are increasing our understanding of the medical and psychosocial risks involved in marrow or PBSC donation and have changed, or are likely to change, clinical practice in the management of adult and pediatric donors.
Most notable in the past two years is the Related Donor Safety (RDSafe) study, supported by the DHSWC and an NIH R01 grant held by committee Chairs, Drs. Pulsipher and Switzer. This study examined many aspects of the donation process on donor outcomes, including severity of adverse events and donor quality of life. It has already led to a number of publications, and more data is forthcoming. Prior to the RDSafe study, no prospective study of a large cohort of related donors had been performed. A few examples of future analyses include a comparison of toxicities experienced by related versus unrelated donors as well as between pediatric related and adult related donors.
A follow-up CIBMTR survey of donor practice patterns has also been completed, leading to changes in international guidelines regarding the work-up and management of adult donors. Based on the important results from this survey, a parallel survey of donor practice patterns in pediatrics is now developed and will be circulated later this year. Other ongoing studies focus on the impact of second donations on donors, the quality of bone marrow harvest on transplant outcomes, and the utility of autologous blood donation in donors.
View planned, in-progress, and completed studies and publications on the Donor Health and Safety Working Committee webpage. Based on the 2015-2016 final review of the Advisory Committee, the DHSWC was given an “outstanding” productivity review.
The DHSWC is pleased to see a steady increase in attendance at the committee meetings over the past three BMT Tandem Meetings. We encourage participation from the transplant community, especially new members, in ongoing studies or through the submission of new proposals.
The BMT Tandem Meetings - the combined annual meetings of the CIBMTR and ASBMT - are North America’s largest international gathering of BMT clinicians and investigators, laboratory technicians, advanced practice professionals, transplant nurses, pharmacists, administrators, and clinical research associates since 1999.
View conference photos.
The 2017 BMT Tandem Meetings celebrated another record-breaking year with nearly 3,500 registered from more than 40 countries! This year the meetings were held February 22-26, at the Gaylord Palms Convention Center in Orlando, Florida. Countries with the highest representation, aside from the United States, were Canada, Brazil, Colombia, and Germany. Forty-eight percent of attendees were first time attendees. Many of the first-time attendees were abstract presenters and live stream attendees, with the rest falling under various categories such as exhibitors, general attendees, and invited faculty.
Program Co-Chairs Marcel van den Brink, MD, PhD, for ASBMT and David Marks, MBBS, PhD, for CIBMTR, along with the Scientific Organizing Committee, put together an excellent program for this year’s meeting. New this year, we closed the BMT Tandem Meetings with three late breaking abstracts. Also included were 5 breakfast symposia and 4 lunch symposia, 5 plenary sessions, 9 concurrent sessions, 96 oral abstracts, 7 product theaters, 6 best abstract awards, 2 poster sessions, 15 Working Committee meetings, and 8 Meet-the-Professor sessions. In addition to an outstanding scientific program, parallel sessions were held for Clinical Research Professionals/Data Managers, BMT CTN Coordinators, BMT CTN Investigators, Pediatricians, Administrative Directors, Transplant Nurses, Pharmacists, and Nurse Practitioners with the addition of a new session this year entitled “Building a PCOR Collaborative Community”.
The CIBMTR Distinguished Service Award was presented jointly to David Gómez-Almaguer, MD, and Guillermo J. Ruiz-Argüelles, MD. They have focused their efforts on making changes to BMT procedures to render them affordable for persons living in developing countries; employing these changes, they have grafted more than 1,000 persons with both malignant and non-malignant diseases. The two have worked together in two different institutions in Mexico. Their partnership has done more to advance the field of stem cell transplanttation in Mexico and Latin America than any other investigators in the region. The purpose of the Distinguished Service Award is to recognize individuals who have made outstanding contributions by promoting transplantation research and care in developing countries, by advancing the field despite unique challenges, by expanding the availability of transplantation, by disseminating research results as a way of improving outcomes and quality of life, or by collaborating with organizations to increase data exchange and research collaborations world-wide. Revista de Hematologia published an article about the award presentation titled Presentation of the 2017 Distinguished Service Awards by the CIBMTR, February 24, 2017 (Hematologia Revista Mexicana 2017 January,18(1):33-35.)
Richard E. Champlin, MD, of the University of Texas MD Anderson Cancer Center in Houston, TX, presented the Mortimer M. Bortin Lecture, speaking on Use and Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Era of Targeted Therapies. The Mortimer M. Bortin Lecture commemorates the Founding Scientific Director of the International Bone Marrow Transplant Registry, now the CIBMTR. Dr. Bortin's foresight and dedication were critical to the development of the CIBMTR as a global resource for HCT research.
Jerome Ritz, MD, presented the E. Donnall Thomas Lecture “Modulating Immune Reconstitution after Stem Cell Transplantation”. In honor of Dr. Thomas, the E. Donnall Thomas Lecture recognizes an eminent physician or scientist, either a clinician or investigator, who has contributed meritoriously to the advancement of BMT knowledge.
ASBMT presented the Lifetime Achievement Award to Hans Messner, MD, PhD, Professor of Medicine at the University of Toronto and Princess Margaret Cancer Center. They also presented three Biology of Blood and Marrow Transplantation Editorial Awards, and seven ASBMT New Investigator Awards.
A new meet and greet opportunity was offered this year with a Networking Reception in the exhibit hall Thursday evening. Attendees enjoyed beverages and visited many of the 74 booths set up in the exhibit hall. The BMT Tandem Reception was held on Saturday evening on the Coquina Lawn and in Wreckers Night Club at the Gaylord Palms where attendees connected with colleagues and danced to the music of the band Blonde Ambition.
Save the date and watch for details on the 2018 BMT Tandem Meetings in Salt Lake City, Utah, in the coming months. Contact Sherry Fisher at firstname.lastname@example.org for information regarding support opportunities for next year’s meeting.
On behalf of the 2018 BMT Tandem Meetings team as well as Scientific Organizing Chairs, Fred Appelbaum, MD, for the CIBMTR and Jerome Ritz, MD, for ASBMT, we look forward to seeing you at the Salt Palace Convention Center in Salt Lake City, Utah, February 21-25, 2018.
By J.D. Rizzo, MD and Vincent Ho, MD
The BMT CTN, with its 20 Core and approximately 100 Affiliate centers, has enrolled more than 9,300 patients. The Network was established in 2001 and is at the end of its third grant cycle funded by the NHLBI and NCI. Last year the NHLBI shared welcome news that the BMT CTN grant would be renewed for a fourth grant cycle. This seven-year cycle starts July 1 and will include 18 Core Centers, several of which are anticipated to still be consortia comprised of two or more centers.
Clinical Trials: Open Enrollment
The BMT CTN encourages widespread transplant community participation in clinical trials. If your center is interested in participating, please visit the BMT CTN website.
There are 11 trials open to accrual, 1 released to centers. and 4 in development. The following BMT CTN trial was recently released to centers:
BMT CTN Publications
There are 73 BMT CTN published articles, including 21 primary analyses. The following primary results manuscripts were recently published.
About the BMT CTN
The CIBMTR shares administration of the BMT CTN Data and Coordinating Center with NMDP/Be The Match® and The Emmes Corporation®. Together, these three organizations support all BMT CTN activities. The BMT CTN Steering Committee is currently under the leadership of Chair Steve Devine, MD, Ohio State University. Rick Jones, MD, Johns Hopkins, is Chair-Elect, and Helen Heslop, MD, Baylor College of Medicine, is Vice-Chair.
To get up-to-date information about BMT CTN studies, meetings, and news:facebook.com/bmtctntwitter.com/bmtctn (@BMTCTN)
Our SupportersThe CIBMTR is supported by Public Health Service Grant/Cooperative Agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research; and grants from our corporate and private contributors.